Notch signaling in the regulation of hematopoietic stem cell by Lampreia, Fabio Pereira et al.
CELL:CELL INTERACTIONS IN STEM CELL MAINTENANCE (D BONNET, SECTION EDITOR)
Notch Signaling in the Regulation of Hematopoietic Stem Cell
Fabio Pereira Lampreia1 & Joana Gonçalves Carmelo1,2 & Fernando Anjos-Afonso1
# The Author(s) 2017. This article is an open access publication
Abstract
Purpose of Review Understanding the signaling pathways
that govern hematopoietic stem and progenitor cells
(HSPCs) is fundamental to uncover their regulation and how
this is skewed in hematological malignancies. Whether Notch
is necessary for the regulation of mammalian HSPCs is still
unclear. We therefore critically review the current literature on
the role of Notch in HSPCs.
Recent Findings HSPCs have shown different requirements
for Notch signals in vitro and in vivo and at different stages of
differentiation. Additionally, bone marrow niche cells activate
Notch signaling in HSPCs enhancing their regenerative and
self-renewal capacity.
Summary Despite the controversy, adequate levels of Notch
signaling appear necessary to avoid the development of hema-
tological malignancies. Contrary to early studies, recent
research suggests that Notch signaling may play a role in
homeostatic and regenerative hematopoiesis but further inves-
tigation is necessary to understand how it is regulated by the
different ligand/receptor pairings and the molecular mecha-
nisms that are triggered.
Keywords Notch signaling . HSC . Niche .MPD
Introduction: Brief Description of Notch Signaling
Detailed reviews on the Notch pathway can be found else-
where [1, 2]. Briefly, in mammals, there are four Notch recep-
tors (Notch1, 2, 3, and 4) and five structurally related, single-
pass membrane Notch ligands (Delta-like1, 3, and 4 and
Jagged1 and 2). The canonical Notch signaling is activated
through ligand-mediated interaction that instigates the first
c leavage of the receptor, which is media ted by
metalloproteases like the tumor necrosis factor alpha-
converting enzyme (TACE). This licenses a second cleavage
mediated by the γ-secretase complex (comprising Nicastrin,
Presenilin 1/2, PEN2 (Presenilin enhancer 2), and APH1 (an-
terior pharynx-defective 1)) that forms the intracellular Notch
receptor domain (N-ICD), which subsequently translocates
into the nucleus and cooperates with the DNA-binding protein
RBPJκ (recombinant binding protein suppressor of hairless;
also known as CSL). This allows the conversion of the tran-
scriptional repressor complex into an activator complex to-
gether with its co-activator Mastermind-like 1 (MAML1),
and other specific co-activators [1, 2]. The activation of
Notch signaling triggers the expression of various target
genes, such as Hes and the Hes-related (HESR/HEY) family
of basic helix-loop-helix transcription repressors [3] and sub-
sequently regulates the expression of other genes. There is a
growing appreciation that this pathway can also be
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orchestrated in a non-canonical manner, via HES- or RBPJk-
HES-independent axis or by other means [4].
First Evidences of Notch Signaling in the Regulation
of HSPC Biology
The blood is one of the most highly regenerative tissues with
an average of 1011–1012 new blood cells being produced daily
in a healthy adult human. With such a high turnover system, a
very fine-tuned production of cells is required to maintain the
homeostasis of the blood system. Studies on signaling path-
ways that govern hematopoietic stem cell (HSC) self-renewal
and fate decisions are critical for this balance and some of the
HSC regulators have been identified including cytokines,
growth factors, transcription factors, cell cycle regulators,
chromatin modifiers, etc. However, the molecular mecha-
nisms in particular the cell-to-cell interactions that support
and regulate HSCs in their microenvironment (niche) are still
largely unexplored [5, 6]. The evolutionarily conserved Notch
signaling pathway functions as a major mediator of cell fate
determination during development and also regulates diverse
cellular functions including differentiation, proliferation, and
survival. In hematopoiesis, the importance of Notch signaling
has been associated with hematological malignancies such as
T cell acute lymphoblastic leukemia [7, 8]. Differently from a
conventional signaling pathway that involves the interaction
between soluble factors and their receptors, Notch signaling
pathway has both ligand and receptors as transmembrane pro-
teins expressed on the cell surface. As such, Notch signaling is
in many ways an ideal candidate pathway for instructing com-
munication between HSCs and their niche, as it requires cell-
to-cell contact for activation.
While known to be required during the development of the
hematopoietic system [9] and in T cell development [10],
whether Notch signaling plays a role in the regulation of adult
hematopoietic stem cells in physiological conditions remains
a subject of active debate mainly due to conflicting results
obtained in several studies. First, Notch ligands and receptors
have been detected in the bone marrow niche [11] and in
HSPCs, respectively, both in mice and humans [12, 13].
Then, when transducing the constitutively active form of
Notch1-intracellular domain (N1-ICD) [14] or the Notch tar-
getHes1 [15] results is an increase in the self-renewal capacity
of HSPCs. Further to this, activation of Notch signaling
through exposure of primitive hematopoietic cells to Notch
ligands in vitro such as Jagged1 [11], extracellular Delta-
like1 ligand [16], and soluble Jagged1 [17] also promotes
stem cell self-renewal and inhibits differentiation.
Based on these early reports, it is therefore tempting to
suggest that Notch signaling might play a role in hematopoi-
esis. Nonetheless, this effect is likely to be the result of super-
physiological levels of Notch signaling in vitro. On the other
hand, in an interesting study, it was reported that the loss of
Itch (an E3 ubiquitin ligase which negatively regulates Notch
signaling by controlling Notch receptor degradation) led to
sustained levels of Notch1-mediated signaling, thus, function-
ing as an indirect Notch gain-of-function approach [18]. As a
result, mice that were transplanted with Itch-deficient
(Lin−Sca1+cKit+) LSK HSPCs had an expanded stem cell
poolwith enhanced hematopoietic contribution up to 24weeks
as compared to control LSK cells.
Despite these positive results that paved the way for ap-
proaches that allowed the development of in vitro HSPCs
expansion protocols [19, 20], the understanding of the func-
tional role of Notch signaling remains unclear as loss of func-
tion approaches have led to the proposal that the Notch path-
way is not required in steady state hematopoiesis, as highlight-
ed below (Table 1), in contrast to the in vitro studies.
While early loss of mouse Notch1 [10] and Rbpj [21] stud-
ies have established the Notch1-RBPJk-HES1 axis as a major
regulator of T cell differentiation, no myeloid and B cell line-
age defects were observed. Although these studies did not
focus onHSCs, Duncan and colleagues showed that LSK cells
from a transgenic Notch reporter (TNR-GFP) mouse have
high Notch activity as evidenced in bone marrow sections
by co-localization of c-kit+ and GFP+ cells and by flow cyto-
metric analysis of primitive LSK cells showing GFP expres-
sion. Interestingly, transplanting murine lineage negative
(Lin−) cells transduced with dominant-negative of Xenopus
suppressor of Xenopus Rbpj homologue (dnXSu(H)) resulted
in the depletion of the HSC population after long-term recon-
stitution compared to control transduced cells [12].
Which Notch ligand/receptor pairing is preferentially used
by HSPCs to signal Notch still remains elusive. Jagged1 is
expressed in the bone marrow niche cells, in particular on
osteoblasts [11, 27••]. Yet, loss of both Jagged1 and Notch1
in the bone marrow had no effect on HSC homeostasis, on
hematopoietic reconstitution after genotoxic insult, or in the
number of cells of different stem and progenitor subsets after
bone marrow transplant thus excluding an essential role for
Jagged1-mediated Notch1 signaling on HSC self-renewal or
differentiation [22]. However, these studies did not rule out
the possible redundant effects from other Notch receptors or
ligands. Indeed, Varnum-Finney and colleagues have demon-
strated that Notch2 but not Notch1 mediates LSK cell self-
renewal, repopulation following transplantation and inhibits
myeloid differentiation. Yet, neither loss of Notch1 nor
Notch2 had any effect on the number of HSCs in steady-
state conditions [24].
Perhaps more convincingly is a study undertaking a pan-
inhibition of all canonical Notch signaling approach mediated
by the overexpression of a dominant negative form of
Mastermind-like 1 (dnMAML1). Using this approach, no ef-
fect on LSK cell function was reported with comparable re-
population capacities as to control [23]. The authors have
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proposed that LSK cells are exposed to very low levels of
Notch signaling in vivo, contrasting to the observations re-
ported by Duncan et al. This could explain the reason why
the loss of canonical Notch does not result in dramatic effects
in vivo and could also justify why in different studies, expos-
ing cells to super-physiological levels of ligands or NICD
in vitro resulted in significant increase in stem cell self-
renewal.
Beyond the divergent data inmice, only recently some light
on the role of Notch pathway in human HSCs in vivo has been
shed. Benveniste et al. directly compared the impact of canon-
ical Notch pathway on human purified HSCs in vitro and
in vivo using the same strategy in both contexts [25••]. By
overexpressing dnMAML1, the authors showed that the con-
tribution to all the hematopoietic lineages in vivo in a xeno-
geneic model was comparable in a competition assay between
control- and dnMAML1-HSCs, despite complete blockage of
T-lineage development. Differently, the overexpression of the
dnMAML1 blocked both T cell development and HSC
maintenance/expansion in vitro. Although the authors appear
to claim similar outcomes to the murine system [23], a close
inspection of the authors’ results could infer a different inter-
pretation. First, the percentage of dnMAML1-HSC population
within the human graft was half as compared to controls.
Second, the total number of dnMAML1 engrafted cells was
more than double compared to controls; hence, the authors
concluded that the total number of engrafted dnMAML1-
HSC was unchanged relative to control HSCs [25••].
However, it can be inferred that it did as the frequency of
dnMAML1-HSC was reduced with concomitant increase in
total differentiated human cells.
Furthermore, the authors did not consider the possibility of
non-canonical functions of the Notch receptors as a compen-
satory mechanism. Indeed, Delta-like1 ligand can rewire
interleukin-6-mediated signal in human CD34+ cells through
as yet unknown non-canonical mechanisms [28]. Also, they
did not study the Notch pathway in human CD34− HSCs or
consider potential non-cell-autonomous effects that could play
a role when Notch signaling is not only inhibited in HSCs.
Indeed, at the top of the human hematopoietic hierarchy resides
a quiescent and immature population, defined as
Lin−CD34−CD38−CD93hi (−/−/+), that has higher Notch ac-
tivity as compared to the more mature but still enriched CD34+
HSCs population (Lin−CD34+CD45RA−CD90+CD49f+). The
engraftment potential of the −/−/+ HSCs increased after admin-
istration of the γ-secretase inhibitor DAPT (a Notch pathway
inhibitor) to the murine host in a xenograft model [26••].
Although more prolonged DAPT administration further in-
creased human engraftment, this occurred at the expense of
the CD34+ cells that are normally derived from the −/−/+
HSCs. These results suggest that the activation of the Notch
pathway is important for the maintenance of the human HSCs
Table 1 Evidences of Notch signaling in HSPC regulation
Study Method Species Effect on general hematopoiesis Effect on HSCs/HSPCs Reference
Notch1 loss of function Mx-Cre Mouse Impaired T cell development;
myeloid and B cell
development is normal
ND [10]
RBPJk loss of function Mx-Cre Mouse Impaired T cell development;
myeloid and B cell
development is normal
ND [21]
Notch inhibition (dnRBPJk
transduced LSK cells)
Transduction LSK cells
with dnMAML1
or dnXSu(H)
Mouse Accelerated differentiation
towards B and myeloid
cell lineages
Depletion of LT-HSC [12]
Jagged1 loss of function
Jagged1/Notch1 loss
of function
Mx-Cre Mouse No effect on progenitor nor
mature lymphoid, myeloid,
and erythroid lineages
Normal LSK function
and numbers
[22]
RBPJk loss of function Mx-Cre Mouse Impaired T cell development;
myeloid and B cell
development is normal
Normal HSC function
and numbers
[23]
Notch1 and 2 loss of function Mx-Cre Mouse Myeloid and B cell
development is normal
in steady-state
Normal HSC function
and numbers
[24]
dnMAML1 transduced HSCs Transduction CB cells
with dnMALM1
Human Impaired T cell development;
myeloid and B cell
development is normal
Reduction in frequency
but increase in HSC
numbers
[25••]
Notch inhibition
(γ-secretase inhibitor)
DAPT (γ-secretase
inhibitor) administration
in vivo
Human Early differentiation of HSPCs Higher engraftment capacity
(increased generation of
CD34+CD38− from
CD34− HSPCs)
[26••]
ND not determined
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repopulation capacity. However, the potential effects induced
by the microenvironment were not determined since DAPT
treatment may have also affected the niche cells.
In summary, these discrepancies underline the necessity for
having more stringent and well-described methods to disrupt
Notch signaling in vivo, but they also highlight a potential
difference between the murine and the human systems.
Loss of Notch Signaling and Myeloproliferative
Disease
In contrast to the above results, several studies using mouse
models, in which different members of the Notch signaling
pathway have been deleted, have demonstrated that defective
Notch in the bone marrowmicroenvironment frequently leads
to the development of a myeloproliferative disease (MPD)
phenotype (Table 2).
One of the earliest reports has shown that Presenilin1
haplo- and Presenilin2-deficient (Psen1+/−Psen2−/−) mice
have an expanded granulocytic compartment, and the animals
develop signs of MPD [29]. Notch receptors are subjected to a
great amount of post-translational modifications. Of those, O-
fucose residues added to the receptors by the FX (Factor 10;
homolog of human GDP-L-fucose synthase) enzyme are a
substrate for further modification by Fringe proteins. FX me-
diates the addition of N-acetylglucosamine residues [36],
which are essential for proper interaction with ligands [37].
Fx−/− mice develop a fucosylation-dependent myeloprolifera-
tive phenotype, with expanded Gr1+ granulocytes and
Ter119+ erythrocytes [31]. Additionally, these mutant mice
have increased common myeloid progenitor (CMP),
granulocyte-macrophage progeni tor (GMP), and
megakaryocyte-erythrocyte progenitor (MEP) compartments,
while the common lymphoid progenitors (CLPs) are signifi-
cantly reduced [31]. Similarly to FX-deficient cells, Pofut
(protein O-fucosyltransferase)-deficient marrow progenitors
have defective O-fucosylation of Notch receptors and have
no ability to bind to Delta-like ligands. Pofut-deficient mice
have increased numbers of neutrophils and reduced lympho-
cytes. However, retrovirally transducing Pofut-deficient cells
with N1-ICD can rescue the T cell development impairment
and the Gr1+ cell expansion, suggesting a role for O-fucose-
dependent Notch1 activity [32]. Interestingly, these observa-
tions suggest that Notch must be important at an earlier stage,
perhaps at the multipotent progenitor stage, where the fine-
tuning of the pathway regulates the lymphoid versus myeloid
cell fate decisions.
In addition, using two Cre lines, MMTV-Cre andMx1-Cre,
Kim and colleagues showed that the loss of Mindbomb-1
(Mib1), an essential component for Notch ligands endocyto-
sis, led to MPD originated from the LSK population [30].
However, transplantation of bone marrow cells from TNR
reporter mice showed that LSKs from reconstituted Mib1-
mutant mice had the same level of Notch activation as wild-
type cells, showing that the MPD is not caused by defective
Notch receptor cleavage in LSK cells. In fact, the constitutive
expression of N1-ICD inMib1-null microenvironment signif-
icantly delayed the development of MPD, suggesting that the
defective Notch signaling between the microenvironment
cells caused the MPD phenotype. Nevertheless, this data sug-
gests that appropriate Notch signaling in the niche cells has an
impact on LSK biology.
Another example relates to Adam10 deletion in the bone
marrow compartment, which leads to both cell-autonomous
and non-cell-autonomous MPD. In both cases, deregulated
Notch pathway triggers granulopoiesis with an expanded
HSC pool [33]. These results suggest that proper Notch sig-
naling must be maintained not only in HSPCs but also in the
bone marrow microenvironment. This entails that Notch sig-
naling is most likely important in the crosstalk between hema-
topoietic and niche cells, whereby the loss of proper Notch
signaling in non-hematopoietic cells results in deregulated
stem and progenitor cell self-renewal and differentiation. An
interesting example is a skin-specific inactivation of Notch1
and Notch2, or Rbpj, which results in a myeloproliferative
disorder with increased immature myeloid cells in the bone
marrow and spleen. This was caused by non-cell autonomous
Table 2 Notch signaling and
MPD: involvement of the
microenvironment
Mouse model Phenotype Effect on stem cells Reference
Psen1+/−/Psen2−/− MPD (expanded granulocytes) Normal side population [29]
MMTV-Cre/Mib1f/f
Mx1-Cre/Mib1f/f
MPD (expanded granulocytes) Expanded LSK [30]
Fx−/− MPD Normal LSK [31]
Mx1-Cre/Pofutf/f Increased neutrophils ND [32]
Mx1-Cre/Adam10f/f MPD (expanded) Expanded LSK [33]
Mx1-Cre/Ncstnf/f CMML-like Expanded LSK [34]
Mx1-Cre/Rbpjf/f
Tie2-Cre/Rbpjf/f
MPD Expanded LSK [35••]
ND not determined
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microenvironmental changes in which the loss of Notch trig-
gered the production of thymic stromal lymphopoietin that led
to increased levels of G-CSF resulting in non-cell-
autonomous MPD [38].
Subsequently, an important work from Aifantis’s group
revealed that mice transplanted with Nicastrin-deficient
HSCs develop a human chronic myelomonocytic leukemia-
like disease with an expanded LSK compartment. This is one
of the few studies that attempted to understand the mecha-
nisms behind this effect, with the demonstration that
Nicastrin-deficient LSK cells showed a derepressed myeloid
program, which is thought to be carried out by HES1-
mediated inhibition of Cebpa and Spi1 expressions [34].
Finally, an elegant study from the Carlesso laboratory
showed that conditional deletion of Rbpj usingMx1-Cre leads
to myeloproliferative disease [35••]. When performing recip-
rocal transplantation experiments, the authors observed that
the mutant-LSK pool was significantly increased but the
GMP, CMP, and MEP subsets were unaffected in wild-type
mice but without signs of splenomegaly and with similar sur-
vival as the control cohort. In contrast, when transplanting
wild-type HSPCs into mutant mice, CMPs and GMPs in the
bonemarrow and spleen were significantly increased similarly
to the parental Rbpj−/− mice, resulting in lethal MPD.
Interestingly, the disease evolved faster after bone marrow
transplant. Additionally, the wild-type LSK pool in Rbpj−/−
recipients was less affected than in parental Rbpj−/− mice or
Rbpj−/− cells transplanted into wild-type mice demonstrating a
cell-autonomous contribution of RBPJ in HSC regulation.
However, this study also demonstrates that cell autonomous
loss of Notch activation is not sufficient to develop myeloid
disease, while loss of Notch signaling in the microenviron-
ment induces lethal MPD in a non-cell-autonomous manner.
Mechanistically, deletion of Rbpj leads to increased expres-
sion of miR-155 in bone marrow niche cells where the NICD/
RBPJ complex acts as a transcription repressor of miR-155.
miR-155 upregulates NF-κB activation by targeting one of its
inhibitors κB-Ras1, leading to increased expression of G-CSF
and TNFα thus, inducing a persistent inflammatory state in
the bone marrow.
In summary, it is remarkable that inhibition of Notch,
through the loss of different regulators of the pathway, seems
to expand the most primitive HSCs. This is probably due to
early differentiation induced by the loss of a quiescent state
imposed by Notch signaling. It will be important to clarify
whether this effect leads to stem cell exhaustion or if in some
cases, stem cells can divide seemingly indefinitely as has been
described before [18]. But most importantly, these studies
demonstrate that Notch activation via Notch ligand-receptor
interactions between niche cells is also required for normal
hematopoiesis. Altogether, these studies highlight the impor-
tance of Notch signaling in the bone marrow microenviron-
ment for the proper regulation of hematopoiesis.
HSC and Niche Crosstalk Via Notch Signaling
Several studies have looked for the presence and functions of
Notch ligands in different bone marrow niche cells (endothe-
lial cells, osteoblasts, and mesenchymal stromal cells) that are
able to support HSPCs in vitro or appear closely associated to
them in vivo.
Indeed, bone marrow endothelial cells express Notch li-
gands and its expression can be regulated by pro-
inflammatory stimuli in vitro and in vivo [39]. In a study by
Fernandez and colleagues, a human bone marrow endothelial
cell line called BBMEC^ and primary human bone marrow
endothelial cells were found to express Jagged ligands. The
capacity of these cells to expand hematopoietic progenitors in
an in vitro co-culture system was dependent on Notch signal-
ing. The authors also demonstrated that the ligand density and
Notch signal intensity could result in different degrees of
HSPCs expansion. Furthermore, in vivo pro-inflammatory
cues (TNFα, LPS) caused an increase of Jagged2 expression
on endothelial cells and Notch1 and Notch2 receptors on he-
matopoietic progenitors, which were associated with in-
creased Notch activation.
Later, Butler and colleagues showed that endothelial cells
are able to support long-term expansion of Notch-activated
(TNR-GFP+) LSK HSPCs, but not Notch1 and Notch2 defec-
tive HSCs (Notch1−/−Notch2−/−CD34−Flt-3−LSK) [40]. The
authors also elegantly showed that HSCs secrete vascular en-
dothelial growth factor A (VEGF-A) when exposed to soluble
stem cell factor in vitro. VEGF-A secreted by HSCs in turn
stimulates the translocation of Jagged2 ligand on the endothe-
lial cell surface, which then supports the expansion of the
HSCs by interacting with Notch1 and Notch2 receptors.
This study also demonstrated that in vivo inhibition of both
VEGFR2 and VE-cadherin, essential for endothelial
angiocrine signaling, resulted in a profound decrease in the
instructive capacity of endothelial cells. This caused impaired
reconstitution of TNR-GFP+ hematopoietic cells after sub-
lethal irradiation due to a significant decrease in the regener-
ation of TNR-GFP+ HSCs, leading to demise of the treated
mice. These results not only support the importance of the
vascular niche but also suggest that during hematopoietic re-
covery, angiocrine expression of Notch ligands by endothelial
cells is essential to balance the expansion and differentiation
of HSCs and also reveal a crosstalk between HSCs and their
niche elements.
In the same vein, Butler’s group showed that in vivo con-
ditional deletion of Jagged1 in endothelial cells (VE-cadherin-
Cre) caused a decrease in the number of phenotypical and
functional HSCs in steady-state, which was associated with
a significant reduction in Notch activation in LSK HSPCs
[41•]. In addition, mutant mice have deficient hematopoietic
recovery after sub-lethal irradiation leading to reduced surviv-
al rate compared to the control group. In vitro co-cultures with
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endothelial cells from mutant mice resulted in greater hema-
topoietic expansion exclusively from differentiated cells with
a significant increase in myeloid cells. These data emphasize
the importance of niche Jagged ligands in balancing expan-
sion and differentiation of HSPCs, demonstrating that Notch
signaling activation by bone marrow endothelial cells through
Jagged1 ligand is essential to maintain homeostatic and regen-
erative hematopoiesis.
Of note, this data contradicts the observations of Mancini
et al. [22], in which conditional deletion of Jagged1 driven by
the Mx1 promoter had no effect on hematopoietic regulation
at steady-state or regenerative conditions. Butler’s group ver-
ified that while the VE-cadherin-Cre efficiently deleted the
floxed Jagged1 in bone marrow endothelial cells, the induc-
ible Mx1-Cre system did not. These data indicate that the
observations of Mancini et al. could be associated to ineffi-
cient deletion of endothelial-specific Jagged1.
Apart from endothelial cells, other bone marrow stromal
cells have also been shown to be associated to HSPC regula-
tion via Notch signaling. A subset of human CD146+
perivascular mesenchymal stromal cells (MSCs) support
long-term culture of functional human HSPCs partially
through Notch activation [42]. Indeed, CD146+ perivascular
cells express high levels of Notch ligand Jagged1.
Accordingly, Notch activation was demonstrated to be signif-
icantly higher in HSPCs co-cultured with CD146+ cells than
in co-cultures with total MSCs or CD146− cells. Moreover,
Notch inhibition with DAPT resulted in decreased HSPCs
number and CFUs and increased B cell differentiation.
These results suggest that CD146+ perivascular cells can also
regulate self-renewal and lineage commitment of HSPCs
through Notch signaling.
Interestingly, a recent study shed some light on the human
bone marrow niche in vivo by analyzing human bone biopsy
specimens and human-mouse xenografts. This study revealed
that HSCs with superior regenerative and self-renewal capac-
ity tend to localize to endosteal regions of the trabecular bone
area (TBA) [27••]. These HSCs have distinct molecular acti-
vation enriched with Notch signaling signature compared to
HSCs localizing in the long bone area (LBA). Particularly
within the TBA, phenotypic human HSCs and HPCs prefer-
entially locate in the endosteal over vascular regions. The
authors also showed that osteoblasts from the TBA have in-
creased expression of Notch ligands Jagged1, Jagged2, and
Delta-like4 compared to osteoblasts from the LBA, consistent
with the HSC activation profile. In particular, a threefold
higher proportion of osteoblasts expressing Jagged1 was de-
tected in the TBA compared to LBA. Additionally, Jagged1-
binding HSPCs were found to have higher CFU capacity and
repopulating capacity. Upon Notch inhibition with DAPT
treatment in vivo, total human engraftment and HSPC num-
bers were not affected in the LBA, whereas there was a sig-
nificant reduction in the TBA, suggesting that only this region
is sensitive to Notch inhibition leading to an overall reduction
in human engraftment in a region-specific manner. These ob-
servations support a critical role of Notch signaling in HSC
regulation through interactions with specific bone marrow
niche cells.
In a subsequent study, further investigation on the role of
endosteal osteoblasts in HSC regulation showed that osteo-
blast ablation (Col2.3Δtk) leads to reduced quiescence,
long-term engraftment, and self-renewal capacity of HSCs
[43]. Moreover, osteoblast ablation in a transgenic chronic
myeloid leukemia mouse model showed accelerated leukemia
progression with reduced survival compared to control mice.
In this mouse model, osteoblasts were found to express high
levels of Jagged1 and co-culture of leukemic or normal HSCs
with stromal cells expressing Jagged1 resulted in reduced cell
cycling and total number of cells. These data suggest that
Jagged1 signaling in the osteogenic niche is essential for
maintaining HSC quiescence and long-term self-renewal
capacity.
Finally, as further evidence of the importance of Notch
ligands in the osteogenic niche, in humanized mice expressing
human Jagged1 in osteoblasts, human HSPC repopulation is
higher than in control mice [44]. In addition, mice with human
Delta-like1-expressing osteoblasts develop severe
osteosclerosis, which suppresses the generation of human B
lymphocytes and also retention of human HSPCs that is likely
due to the severe osteosclerosis in the bone marrow [45].
Together, these studies focusing on the osteogenic niche
suggest a role for Notch signaling through osteoblasts on reg-
ulation of HSC self-renewal and quiescence, particularly
through Jagged1 in the trabecular bone area, where interac-
tions and Notch activation seem to be higher. However, the
activated Notch receptors and the molecular mechanisms be-
hind this regulation are still not understood. Also, a more
comprehensive study is necessary to clearly identify the func-
tions of the different ligands on HSPC regulation both in vitro
and in vivo.
Conclusions
Although several authors have suggested Notch signaling as
dispensable in the adult hematopoietic pathway using differ-
ent genetic approaches, the maintenance of adequate dose of
Notch signaling seems fundamental in order to avoid the de-
velopment of hematological malignancies. As reported, differ-
ent populations within the primitive hematopoietic stem and
progenitor compartments seem to depend differently on Notch
at different stages of differentiation. As already mentioned, it
will be relevant to understand the functions of the different
ligand/receptor pairings in different primitive populations. We
have reviewed some studies that have shed light on the mech-
anisms by which Notch regulate HSPCs, and will certainly
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learn more about the fine-tuning of this signaling pathway as
soon as more stringent and well-described methods to inhibit
and activate Notch become available.
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